
Biotech Business - January 12, 2022
Affibody and Lokon Pharma initiate collaboration
Lokon Pharma has announced a collaboration with Affibody to combine oncolytic viruses with Affibody molecules. “Lokon’s oncolytic adenovirus platform encodes human immunostimulatory genes to induce anti-tumor immunity in cancer patients. We already have one virus in clinical development, LOAd703, and we are expanding our pipeline to meet the demand of different types of malignancies” says […]